Pubertal delay in male nonhuman primates (Macaca mulatta) treated with methylphenidate
- aEpidemiology Branch, Division of Epidemiology, Statistics, and Prevention Research, The Eunice Kennedy Shriver National Institute for Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892;
- bDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Women's Research Institute, University of Pittsburgh, Pittsburgh, PA 15213;
- cNational Center for Toxicological Research, Jefferson, AR 72079;
- dToxicologic Pathology Associates, Jefferson, AR 72079;
- eBionetics Corporation, Jefferson, AR 72079;
- fDivision of Applied Research and Technology, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Cincinnati, OH 45226; and
- gNational Institute of Mental Health, Bethesda, MD 20892-9633
See allHide authors and affiliations
Edited by Bruce S. McEwen, The Rockefeller University, New York, NY, and approved August 22, 2011 (received for review February 14, 2011)

Abstract
Juvenile male rhesus monkeys treated with methylphenidate hydrochloride (MPH) to evaluate genetic and behavioral toxicity were observed after 14 mo of treatment to have delayed pubertal progression with impaired testicular descent and reduced testicular volume. Further evaluation of animals dosed orally twice a day with (i) 0.5 mL/kg of vehicle (n = 10), (ii) 0.15 mg/kg of MPH increased to 2.5 mg/kg (low dose, n = 10), or (iii) 1.5 mg/kg of MPH increased to 12.5 mg/kg (high dose, n = 10) for a total of 40 mo revealed that testicular volume was significantly reduced (P < 0.05) at months 15 to 19 and month 27. Testicular descent was significantly delayed (P < 0.05) in the high-dose group. Significantly lower serum testosterone levels were detected in both the low- (P = 0.0017) and high-dose (P = 0.0011) animals through month 33 of treatment. Although serum inhibin B levels were increased overall in low-dose animals (P = 0.0328), differences between groups disappeared by the end of the study. Our findings indicate that MPH administration, beginning before puberty, and which produced clinically relevant blood levels of the drug, impaired pubertal testicular development until ∼5 y of age. It was not possible to resolve whether MPH delayed the initiation of the onset of puberty or reduced the early tempo of the developmental process. Regardless, deficits in testicular volume and hormone secretion disappeared over the 40-mo observation period, suggesting that the impact of MPH on puberty is not permanent.
Footnotes
- ↵1To whom correspondence should be addressed. E-mail: mattisod{at}mail.nih.gov.
Author contributions: D.R.M., T.M.P., J.J.C., D.D., W.S., C.E.H., B.V., and S.M.M. designed research; N.C.T., R.E.P., C.E.H., R.J.C., S.M.S., and T.W.T. performed research; H.-M.L., H.C.C., and J.J.C. analyzed data; and D.R.M., T.M.P., H.-M.L., H.-C.C., J.J.C., S.M.S., J.S.K., B.V., D.M.P., and S.M.M. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1102187108/-/DCSupplemental.
Freely available online through the PNAS open access option.